The Uromigos
Broadcasting the latest developments in GU cancer Hosted by Brian Rini and Tom Powles Brian Rini MD is a Professor of Cancer Research and Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Center Tom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London
Episode 447: ESMO 2025 - RAMPART
James Larkin joins to discuss adjuvant durva/treme vs observation in high risk resected RCC
Episode 446: ESMO 2025 - OPTIC and front-line RCC triplets
Cristina Rodriguez joins us to discuss her data on front-line triplets, and we also discuss the prospective RNAseq-based biomarker OPTIC study
Episode 445: ESMO 2025 - Systemic Checkpoint Inhibition plus BCG in NMIBC (POTOMAC and ALBAN)
Brad McGregor joins us on the heels of his #ESMO25 discussion of these important data in the NMIBC landscape.
Episode 444: ESMO 2025 Preview - Prostate and Renal Cancer
Silke joins us to discuss some important data being presented in prostate cancer. Brian and Tom also cover the RCC data at ESMO 2025
Episode 443: ESMO 2025 Bladder Cancer Preview
Tom and Brian preview the practice-changing bladder cancer data to be presented at ESMO 2025 in Berlin
Episode 441: The History of IO in Urothelial Cancer - Part 2
Jonathan Rosenberg returns to finish this two-part series on IO drug development in urothelial cancer
Episode 440: The History of IO in Urothelial Cancer - Part 1
Jonathan Rosenberg joins in this 2-part series on the history of IO-based therapy in Urothelial Cancer
Episode 439: Transcriptome Expression and Treatment Sensitivity in Prostate Cancer
Gert Attard joins the show to discuss his recent Cell publication looking at tumor transcriptome-wide expression classifiers in advanced prostate cancer.
Episode 438: The History of Testis Cancer Treatment
Christian Kollmannsberger joins us to walk through decades of advances in advanced testis cancer.
Episode 437: Uromigos Japan - バルバーサ (Erdafitinib)を実臨床でどう使うか！
Erdafitinibがついに承認されましたが、依然として多くのCQが残されています。日常診療に役立つ最新のデータをもとに、その活用法についてディスカッションしました。
Episode 436: The History of IO in RCC - Part 2
We continue our conversation with Mike Atkins and David McDermott, discussing IO-based combination therapy in RCC.
Episode 435: The History of IO in RCC - Part 1
The fathers of IO therapy in RCC - Michael Atkins and David McDermott - join us to take a tour through IO development in RCC over the last 20 years.
Episode 434: IMPACT series - A Walk Through the History of VEGF TKI Development in RCC
Danny Heng joins to tour through VEGF TKI drug development from sorafenib to tivozanib and everything in between.
Episode 433: Uromigos Japan - 改訂版ASCO mCRPCガイドライン
5月に改訂されたASCOのmCRPC薬物療法のガイドラインについて3人でディスカッションしました！！評価はいかに？
Episode 432: ASCO 2025 Rapid Oral Session RCC/Bladder Recap
Karie Runcie, MD joins us after chairing the ASCO 2025 rapid oral session to discuss the rcc/bladder presentations.
Episode 432: Recap of the ASCO Rapid Oral RCC/Bladder Session
Karie Runcie, MD joins us to discuss the ASCO rapid oral rcc/bladder session she moderated at ASCO 2025
Episode 431: IMPACT series - Axel Bex on Impactful RCC Clinical Trials
Axel Bex joins the show to discuss trials that he thinks have impacted RCC. We also discuss consolidative approaches, neoadjuvant trials and what can impact an academic career.
Episode 430: Structured Exercise Improves DFS/OS after Adjuvant Therapy in Colorectal Cancer - Does This Apply to GU Cancers?
Chris Booth joins the show to discuss his recent NEJM paper that demonstrated significant DFS and OS improvements with a structured exercise program after adjuvant chemo in colorectal cancer. We discuss implications for GU and other malignancies.
Episode 429: ASCO2025レポート
ASCO2025の注目演題を取り上げ解説、ディスカッションしました！
Episode 428: ASCO 2025 Recap
Brian, Tom and Silke discuss their highlights form ASCO 2025
Episode 427: Emerging Data in Non-muscle Invasive Bladder Cancer (NMIBC)
Josh Meeks joins us to give stellar overview of the emerging data in this space. We also discuss the recent ODAC ruling for lower risk patients.
Episode 426 - ASCO 2025: AMPLITUDE Phase 3 of PARPi in mHSPC
Gert Attard joins us to discuss this practice-changing data and the highlight of ASCO 2025
Episode 425: ASCO 2025 - AI-enabled selection of patients for benefit of ADT + ARPI
Nick James discusses intriguing data from STAMPEDE to us AI to analyze pathology slides to predict benefit from ADT + abiraterone
Episode 424: ASCO 2025 - Emergency podcast on the prostate rapid oral session
Jorge Garcia joins us to discuss the process of selecting abstracts for oral presentation and select highlights from this session.
Episode 423: ASCO 2025 - Casdatifan plus Cabo in refractory RCC
Toni Choueiri discusses this combination cohort of HIF inhibition plus VEGF-R inhibition.
Episode 422: ACSO 2025 - ctDNA data from NIAGARA
Matt Galsky discusses the ASCO 2025 data regarding ctDNA from the NIAGARA neoadjuvant chemo +/- durvalumab study.
Episode 421: ASCO 2025 - Maintenance Avelumab +/- SG in Advanced Bladder Cancer
Jeannie Hoffman-Censits discusses her randomized phase 2 adding SG to maintenence avelumab in mUC.
Episode 420: ASCO 2025 - CheckMate 901: Ipi/Nivo vs chemo for Cis-ineligible metastatic urothelial cancer
Michiel Van Der Heijden joins us to discuss the Ipi/Nivo vs chemo randomization in this trial from his ASCO 2025 presentation
Episode 419: ASCO 2025 - Correlate data from the IMmotion 010 RCC adjuvant study
Monty Pal discusses more correlates from this trial including matched baseline and progression tissue samples.
Episode 418: ASCO 2025 - Biomarkers in RCC
David McDermott joins us on the heels of his outstanding discussion of the clinical science symposium on RCC biomarkers.
Episode 417: ASCO25 GUの注目演題について3人でDiscussion！！
Practice Changing? 独断と偏見で選んだ注目演題について結果の予想も含めて議論しました。
Episode 416: ASCO 2025 Preview
Silke, Tom and Brian discuss what they are looking forward to at ASCO 2025
Episode 415: Uromigos Score 前立腺がん編
日本と海外の違いはあるのか？mHSPCとmCRPCのUromigos Scoreについて激論！！
Episode 414: Uromigos score en cáncer de próstata metastasico - más allá de las guías clínicas
Edición especial en castellano con Alfonso Gómez de Liaño y Guillermo de Velasco. David Lorente da su visión sobre el nuevo Uromigos Score, que clasifica distintas opciones de tratamiento en varios escenarios de cáncer de próstata metastásico
Episode 413: The Uromigos Score for Advanced Prostate Cancer
Silke and Chris joins us to discuss our latest 'Uromigos Score' in which experts score the value of treatments for advanced prostate cancer. Several interesting themes emerge.
Episode 410: AUA 2025 - BOND-003 Cohort C: Cretostimogene in BCG-Unresponsive NMIBC
Mark Tyson from Mayo Clinic joins the podcast to discuss this replicating adenovirus and a high CR rate in BCG-unresponsive NMIBC
Episode 412: AUA 2025 - TAR-200 Monotherapy in BCG-Unresponsive NMUIBC from SunRISe-1
Joe Jacob joins the show to discuss the longer-term follow up of this cohort from SunRISe-1. We discuss definitions of CR and regulatory issues around drug approval in this space as well.
Episode 411: Live from EIKCS in Amsterdam - RCC Highlights
Viktor Grunwald joins to discuss the new data session from EIKCS
Episode 410: AUA 2025 - BOND-003 Cohort C: Cretostimogene in BCG-Unresponsive NMIBC
Mark Tyson from Mayo Clinic joins the podcast to discuss this replicating adenovirus and a high CR rate in BCG-unresponsive NMIBC
Episode 409: AUA 2025 - CREST - BCG +/- Sasanlimab in high-risk NMIBC
Neal Shore joins the show to discuss these exciting data from the American Urological Association Annual Meeting
